Marc Dall'Era, M.D.

Marc A. Dall'Era, M.D.



Urologic Oncology





  • Associate Professor and Vice Chair of Urology
To see if Marc A. Dall'Era is accepting new patients, or for assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

Lawrence J. Ellison Ambulatory Care Center

4860 Y St., Suite 2200
Sacramento, CA 95817
Driving Directions

Primary Phone:

UC Davis Comprehensive Cancer Center

2279 45th Street
Sacramento, CA 95817
Driving Directions

Primary Phone:

4501 X St.
Sacramento, CA 95817
Driving Directions

Primary Phone:

UC Davis Midtown Ambulatory Care Center

3160 Folsom Blvd, Suite 1400
Sacramento, CA 95816
Driving Directions

Primary Phone:

Additional Phone Numbers

Physician Referrals: 800-362-5566

Clinical Interests

Dr. Dall’Era specializes in the management of malignant disease of the urinary tract. 

The specialty care Dr. Dall’Era offers includes:

  • Multi-disciplinary and comprehensive care of patients with urologic malignancy
  • Active surveillance for low risk prostate cancer
  • Multi-parametric MRI/US fusion targeted prostate biopsy
  • Blue Light Fluorescent cystoscopy for bladder cancer with Cysview
  • Minimally invasive and robotic surgery of the kidney and prostate including prostatectomy, partial nephrectomy, pyeloplasty/ureteral reconstruction
  • Radical cystectomy and neobladder creation
  • Advanced genomics testing of urologic cancers


Research/Academic Interests

Dr. Dall'Era's research interests include active surveillance for prostate cancer including utilization of mp-MRI and biomarker discovery and validation. He is also involved in translational research for urothelial cancer diagnosis and management including advanced genomics analysis of bladder tumor.



Center/Program Affiliation

Robotic Surgery Program
UC Davis Comprehensive Cancer Center
UC Davis Medical Group


M.D., UC Davis, Davis CA 2000

B.S., UC Davis, Davis CA 1995


Urology, University of Washington, Seattle WA 2001-2005

Chief Resident, University of Washington, Seattle WA 2005-2006


Oncology, UC San Francisco, San Francisco CA 2006-2008

Board Certifications

American Board of Urology,

Professional Memberships

American Urological Association

Society of Urologic Oncology

Western Section, American Urological Association

Select Recent Publications

To view a detailed list of  Dr. Dall'Era's publications, please click here.

Dall’Era MA, Maddala T, Polychronopoulos L, Gallagher JR, Febbo PG, Denes BS. Utility of the Oncotype DX Prostate Cancer Assay in Clinical Practice for Treatment Selection in Men Newly Diagnosed with Prostate Cancer: A retrospective Chart Review Analysis. Urology Practice. 2015;2,343-348.

Yuh L, Dall’Era MA, Penson DF, Evan CP. Active Surveillance for Prostate Cancer Under the Patient Protection and Affordable Act. Urology Practice. 2015;2(4):154-159.

Pugashetti N, Yap SA, Lara PN, Gandour-Edwards R, Dall’Era MA. Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumour. Canadian Urological Association Journal. 2015;9(3-4):E204-207.

Belair CD, Paikari A, Moltzahn F, Shenoy A, Yau C, Dall’Era M, Simko J, Benz C, Blelloch R. DGCR8 is Essential for Tumor Progression following PTEN loss in the prostate. EMBO. 2015;16(9):1219-32.

Tomlinson B, Lin TY, Dall’Era M, Pan CX. Nanotechnology in Bladder Cancer: Current State of Development and Clinical Practice. Nanomedicine (Lond). 2015;10(7):1189-1201.

Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer. 2014;120(6):818-23.

Dall'Era MA. The economics of active surveillance for prostate cancer. Curr Opin Urol. 2013;23(3):278-82. Review.

Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012;62(6):976-83. Review.

Keegan KA, Dall'Era MA, Durbin-Johnson B, Evans CP. Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Cancer. 2012;118(14):3512-8.

Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE Jr, Wallace ME, Kantoff PW, Carroll PR. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008;112(8):1650-9. Review.